Median Technologies has forged a collaboration with Tempus AI to broaden access in the United States to its FDA-cleared eyonis® LCS software as a medical device, a high-performance artificial intelligence tool designed for lung cancer screening and diagnosis.
Under the agreement, Tempus will distribute eyonis® LCS to U.S. imaging providers through the Tempus Pixel platform, an AI-enabled clinical imaging solution that integrates advanced analysis, automated reporting and lesion quantification into radiological workflows. This arrangement is intended to support implementation, onboarding and integration of the lung cancer screening software into routine clinical practice.
The collaboration follows the software’s recent clearance by the U.S. Food and Drug Administration under the 510(k) pathway, marking eyonis® LCS as an AI-based computer-aided detection and diagnosis device capable of identifying and characterising lung cancer findings in low-dose CT scans with high sensitivity and specificity.
The distribution partnership builds on existing reimbursement pathways and targets the broader deployment of this AI-driven screening technology across eligible patient populations nationwide.
As part of the arrangement, both companies will share revenues generated through the use of eyonis® LCS, while Median Technologies continues to progress regulatory and commercial strategies for the U.S. rollout. The partnership also lays groundwork for extending access across European markets as regulatory approvals evolve.
Also Read